| Hans-Günter Meyer-Thompson | Verschiedene
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
Chiappini S, d'Andrea G, De Filippis S, Di Nicola M, Andriola I, Bassetti R, Barlati S, Pettorruso M, Sensi S, Clerici M, Dell'Osso B, Vita A, Martinotti G.
Eur Neuropsychopharmacol. 2023 May 4;74:15-21. doi: 10.1016/j.euroneuro.2023.04.011. Epub ahead of print. PMID: 37148637.
https://www.sciencedirect.com/science/article/pii/S0924977X23000779